Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.48 |
| ▸ | MMP12 | P39900 | 5/20 | 0.48 |
| ▸ | MMP1 | P03956 | 5/20 | 0.48 |
| ▸ | MMP9 | P14780 | 4/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16661268 | 0.81 | TDP1 (0.41) | MMP2MMP12MMP1MMP9TDP1 | |
| SCHEMBL9940321 | 0.76 | PIN1 (0.67) | PIN1ALDH1A1 | |
| SCHEMBL17772403 | 0.76 | PIN1 (0.33) | PIN1 | |
| SCHEMBL20181861 | 0.76 | MMP2 (0.55) | MMP2MMP12MMP1MMP9TDP1 | |
| SCHEMBL22479156 | 0.74 | KDM4E (0.48) | MMP2MMP12MMP1MMP9TDP1 | |
| SCHEMBL21442370 | 0.74 | MMP2 (0.58) | MMP2MMP12MMP1MMP9TDP1 | |
| SCHEMBL4081417 | 0.73 | PIN1 (0.62) | MMP2PIN1KMT2ATSHRLMNA | |
| SCHEMBL20173265 | 0.73 | MMP2 (0.51) | MMP2MMP12MMP1MMP9TDP1 | |
| SCHEMBL4893631 | 0.73 | PIN1 (0.66) | MMP2MMP1MMP9PIN1KMT2A | |
| SCHEMBL23682708 | 0.71 | MMP2 (0.49) | MMP2MMP12MMP1MMP9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-2651915-B1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-2651915-B1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| CN-103261185-B | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORP | 2014-12-10 | — | — | CN | disclosed |
| EP-2651915-A1 | CONTINUOUS ARYCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| CN-103261185-A | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORP | 2013-08-21 | — | — | CN | disclosed |
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | MMP2 2301/4885MMP12 2115/4885MMP1 2119/4885 |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | MMP2 2301/4885MMP12 2115/4885MMP1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.